V3381CC
Summary
V3381 is a novel dual-acting NMDA antagonist & MAO inhibitor, originally licensed from Chiesi Farmaceutici (Chiesi) and is being evaluated in patients with chronic cough.
Background
Chronic cough affects between 10-20% of the non-smoking population. Chronic intractable cough is an under-recognised and under-treated phenomenon. Chronic cough patients have on average a cough history of greater than six years, and report many physician contacts, with multiple investigations and unsuccessful trials of treatment. Chronic cough also substantially impacts on a patient’s quality of life with an average of 240 coughs in a 24 hour period, half are clinically depressed, and two thirds of women with chronic cough have urinary incontinence.
Clinical Studies
A pilot study, run in collaboration with Professor Ashley Woodcock from the University Hospitals of South Manchester NHS Foundation, is being conducted specifically in patients with chronic cough who do not have an obvious underlying reason for the cough, such as a persistent chest infection, asthma or gastro-oesophageal reflux. This type of cough is believed to be caused by over-sensitivity of the nerves supplying the respiratory tract and so has many parallels with neuropathic pain.
The study will be conducted in up to 20 patients with chronic cough and will utilise a new objective cough monitor developed by Professor Woodcock’s team to determine whether indantadol is likely to have any effect on cough frequency. If the pilot study indicates an effect, further randomised studies may be conducted.
